Summary
Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic catheters, steerable guidewires and PTCA Balloons. It also offers products such as access accessories, vena cava filters, crossing devices, guiding catheters, PTA balloons, self expanding stents, specialty balloons, hydrophilic nitinol guidewire, balloon expandable stents, transhepatic biliary stent, carotid stent system and vascular closure devices among others. The company has operations in Japan, Canada, Europe, Middle East and Africa. Cordis is headquartered in Fremont, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cordis Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cordis Corp Company Overview 6
Cordis Corp Company Snapshot 6
Cordis Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Cordis Corp – Pipeline Analysis Overview 9
Cordis Corp - Key Facts 9
Cordis Corp - Major Products and Services 10
Cordis Corp Pipeline Products by Development Stage 11
Cordis Corp Ongoing Clinical Trials by Trial Status 13
Cordis Corp Pipeline Products Overview 15
Corio Pimecrolimus-eluting Stent 15
Corio Pimecrolimus-eluting Stent Product Overview 15
CYPHER ELITE 16
CYPHER ELITE Product Overview 16
ELITECROSS Support Catheter 17
ELITECROSS Support Catheter Product Overview 17
EP Contact Force Sensing Catheter Enabled By CARTO 3 18
EP Contact Force Sensing Catheter Enabled By CARTO 3 Product Overview 18
EP Lesion Assessment Device 19
EP Lesion Assessment Device Product Overview 19
FlexStent Femoropopliteal Self Expanding Stent System - SFA 20
FlexStent Femoropopliteal Self Expanding Stent System - SFA Product Overview 20
FlexStent Femoropopliteal Self Expanding Stent System - SFA Clinical Trial 21
FlexStent Self Expanding Below-The-Knee Venous Stent System 22
FlexStent Self Expanding Below-The-Knee Venous Stent System Product Overview 22
FlexStent Self Expanding Venous Stent System 23
FlexStent Self Expanding Venous Stent System Product Overview 23
Flow Diverter 24
Flow Diverter Product Overview 24
INCRAFT AAA Stent Graft 25
INCRAFT AAA Stent Graft Product Overview 25
INCRAFT AAA Stent Graft Clinical Trial 26
NEVO Sirolimus-Eluting Coronary Stent 27
NEVO Sirolimus-Eluting Coronary Stent Product Overview 27
Next Generation Coronary Stent 28
Next Generation Coronary Stent Product Overview 28
Next Generation EMPIRA PTCA Balloon 29
Next Generation EMPIRA PTCA Balloon Product Overview 29
NOGA Guided Myostar Injection Catheter 30
NOGA Guided Myostar Injection Catheter Product Overview 30
NOGA Guided Myostar Injection Catheter Clinical Trial 31
SymBio Pimecrolimus/Paclitaxel-eluting Stent 32
SymBio Pimecrolimus/Paclitaxel-eluting Stent Product Overview 32
Tibial SE FlexStent 33
Tibial SE FlexStent Product Overview 33
Cordis Corp - Key Competitors 34
Cordis Corp - Key Employees 35
Cordis Corp - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Cordis Corp, Recent Developments 37
May 12, 2016: Biosensors Announces Strategic Agreement With Cardinal Health 37
Mar 04, 2016: Palmaz Scientific Announces Chapter 11 Filing; Seeks Prospective Buyers for Its Breakthrough Technology 37
Nov 19, 2015: Strong Results Reported for the Cordis INCRAFT AAA Stent Graft System with New Four-Year Data from the INNOVATION Trial 38
Oct 09, 2015: Cardinal Health and Cordis Debut Combined Offering of Cardiovascular Product Advances at TCT 2015 39
Jun 08, 2015: Cordis Expands Crossing Portfolio by the launch of OUTBACK Elite Re-Entry Catheter for the Treatment of Chronic Total Occlusions 39
Jun 08, 2015: Cordis Expands Crossing Portfolio by the Launch of ELITECROSS Support Catheter for the Treatment of Chronic Total Occlusions 40
Jan 05, 2015: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Cordis 41
Nov 19, 2014: Cordis Leads With Strong Podium Presence At VEITH 2014 With Presentation Of S.M.A.R.T. Stent Data 41
Nov 19, 2014: Cordis Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT System Data 41
Sep 10, 2014: Cordis Launches INCRAFT AAA Stent Graft System for Treatment of Abdominal Aortic Aneurysms 42
Appendix 43
Methodology 43
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Cordis Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Cordis Corp Pipeline Products by Equipment Type 7
Cordis Corp Pipeline Products by Indication 8
Cordis Corp Ongoing Clinical Trials by Trial Status 8
Cordis Corp, Key Facts 9
Cordis Corp, Major Products and Services 10
Cordis Corp Number of Pipeline Products by Development Stage 11
Cordis Corp Pipeline Products Summary by Development Stage 12
Cordis Corp Ongoing Clinical Trials by Trial Status 13
Cordis Corp Ongoing Clinical Trials Summary 14
Corio Pimecrolimus-eluting Stent - Product Status 15
Corio Pimecrolimus-eluting Stent - Product Description 15
CYPHER ELITE - Product Status 16
CYPHER ELITE - Product Description 16
ELITECROSS Support Catheter - Product Status 17
ELITECROSS Support Catheter - Product Description 17
EP Contact Force Sensing Catheter Enabled By CARTO 3 - Product Status 18
EP Contact Force Sensing Catheter Enabled By CARTO 3 - Product Description 18
EP Lesion Assessment Device - Product Status 19
EP Lesion Assessment Device - Product Description 19
FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status 20
FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description 20
FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study 21
FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status 22
FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description 22
FlexStent Self Expanding Venous Stent System - Product Status 23
FlexStent Self Expanding Venous Stent System - Product Description 23
Flow Diverter - Product Status 24
Flow Diverter - Product Description 24
INCRAFT AAA Stent Graft - Product Status 25
INCRAFT AAA Stent Graft - Product Description 25
INCRAFT AAA Stent Graft - A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft Stent Graft System in Subjects with Abdominal Aortic Aneurysms (INSPIRATION) 26
INCRAFT AAA Stent Graft - A Multicenter, Open Label, Prospective, Post Approval Study of the INCRAFT Abdominal Aortic Aneurysm (AAA) Stent Graft System in Subjects with Abdominal Aortic Aneurysms 26
INCRAFT AAA Stent Graft - Compassionate Use of the Incraft AAA Stent Graft System 26
NEVO Sirolimus-Eluting Coronary Stent - Product Status 27
NEVO Sirolimus-Eluting Coronary Stent - Product Description 27
Next Generation Coronary Stent - Product Status 28
Next Generation Coronary Stent - Product Description 28
Next Generation EMPIRA PTCA Balloon - Product Status 29
Next Generation EMPIRA PTCA Balloon - Product Description 29
NOGA Guided Myostar Injection Catheter - Product Status 30
NOGA Guided Myostar Injection Catheter - Product Description 30
NOGA Guided Myostar Injection Catheter - A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction 31
SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Status 32
SymBio Pimecrolimus/Paclitaxel-eluting Stent - Product Description 32
Tibial SE FlexStent - Product Status 33
Tibial SE FlexStent - Product Description 33
Cordis Corp, Key Employees 35
Cordis Corp, Other Locations 36
Glossary 44
List of Figures
Cordis Corp Pipeline Products by Equipment Type 7
Cordis Corp Pipeline Products by Development Stage 11
Cordis Corp Ongoing Clinical Trials by Trial Status 13
